Abstract:Significance Impaired neuronal bioenergetics and neuroinflammation are thought to play key roles in the progression of Alzheimer's disease (AD), but their interplay is not clear. AD mouse brains showed lower nicotinamide adenine dinucleotide (NAD+) levels and alterations in inflammation. Treatment of AD mice with NR reduced neuroinflammation, attenuated DNA damage, and prevented cellular senescence. We present evidence that the beneficial effects of nicotinamide riboside (NR) are, in part, through a cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING)-dependent pathway. DNA damage was increased in AD and attenuated by NR. Both cGAS–STING and NAD+ pathways are potential therapeutic targets for AD. Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disorder. Impaired neuronal bioenergetics and neuroinflammation are thought to play key roles in the progression of AD, but their interplay is not clear. Nicotinamide adenine dinucleotide (NAD+) is an important metabolite in all human cells in which it is pivotal for multiple processes including DNA repair and mitophagy, both of which are impaired in AD neurons. Here, we report that levels of NAD+ are reduced and markers of inflammation increased in the brains of APP/PS1 mutant transgenic mice with beta-amyloid pathology. Treatment of APP/PS1 mutant mice with the NAD+ precursor nicotinamide riboside (NR) for 5 mo increased brain NAD+ levels, reduced expression of proinflammatory cytokines, and decreased activation of microglia and astrocytes. NR treatment also reduced NLRP3 inflammasome expression, DNA damage, apoptosis, and cellular senescence in the AD mouse brains. Activation of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) are associated with DNA damage and senescence. cGAS–STING elevation was observed in the AD mice and normalized by NR treatment. Cell culture experiments using microglia suggested that the beneficial effects of NR are, in part, through a cGAS–STING-dependent pathway. Levels of ectopic (cytoplasmic) DNA were increased in APP/PS1 mutant mice and human AD fibroblasts and down-regulated by NR. NR treatment induced mitophagy and improved cognitive and synaptic functions in APP/PS1 mutant mice. Our findings suggest a role for NAD+ depletion-mediated activation of cGAS–STING in neuroinflammation and cellular senescence in AD.

Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome

NAD activates renal metabolism and protects from chronic kidney disease in a model of Alport syndrome

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury

Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease

Impaired Nicotinamide Adenine Dinucleotide Biosynthesis in the Kidney of Chronic Kidney Disease

Nicotinamide riboside: A promising therapy for MI-induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase-mediated NAD levels

The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease

NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease

Nicotinamide mononucleotide ameliorates adriamycin-induced renal damage by epigenetically suppressing the NMN/NAD consumers mediated by Twist2

Eliciting the Mitochondrial Unfolded Protein Response by Nicotinamide Adenine Dinucleotide Repletion Reverses Fatty Liver Disease in Mice

Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy

NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells

Overexpression of NRK1 Ameliorates Diet- and Age-Induced Hepatic Steatosis and Insulin Resistance.

Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration

Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data

Effect of NAD+ boosting on kidney ischemia-reperfusion injury

Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence

NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS–STING

Nicotinamide Riboside Protects Against Liver Fibrosis Induced by CCl4 Via Regulating the Acetylation of Smads Signaling Pathway.

Hepatocyte-specific perturbation of NAD+ biosynthetic pathways in mice induces reversible nonalcoholic steatohepatitis-like phenotypes